ESR1 and breast carcinoma: Notably, in the WHEL study, the upper high-sensitivity CRP (hsCRP) levels (≥ 10 mg/L) were associated with a 65% increased risk of additional breast cancer events vs. no inflammation levels (< 1.0 mg/L) (HR 1.65, 95% CI 1.15–2.38, p = 0.03, full model adjusted for age, time since diagnosis, disease stage, disease grade, race–ethnicity, BMI, anti-estrogen use, and ER/PR status) [27].